Viewing Study NCT03708003


Ignite Creation Date: 2025-12-24 @ 7:25 PM
Ignite Modification Date: 2025-12-25 @ 5:05 PM
Study NCT ID: NCT03708003
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-27
First Post: 2018-10-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Sponsor: Swiss Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module